Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer

INTRODUCTION: Metastatic breast cancer (MBC) is a diverse disease. Therapeutic options include hormonal therapy, chemotherapy, and targeted therapies. The optimal treatment sequence for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancer remains unknown. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Mahmasani, Layal, Amhaz, Ghid, Abou Zeidane, Reine, Chamseddine, Nathalie, Hatab, Taha, Sabbagh, Saad, Charafeddine, Maya, Assi, Hazem I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619648/
https://www.ncbi.nlm.nih.gov/pubmed/37920158
http://dx.doi.org/10.3389/fonc.2023.1181375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619648/
https://www.ncbi.nlm.nih.gov/pubmed/37920158
http://dx.doi.org/10.3389/fonc.2023.1181375

Ejemplares similares